REGN REGENERON PHARMACEUTICALS, INC.: institutional ownership and insider trading
1,476 funds reported holding $67.9B of REGENERON PHARMACEUTICALS, INC. in their latest 13F filings; in Q2 2026 funds net bought $2.27B, with 109 new positions and 169 funds selling out; over the last 12 months insiders bought $0 and sold $16.1M on the open market; over its last four quarters it reported revenue of $15.5B and net income of $4.33B.
REGN revenue and earnings
- Quarter ended Jun 30, 2026: revenue $4.29B, net income $1.30B, EPS 12.23
- Quarter ended Mar 31, 2026: revenue $3.61B, net income $727M, EPS 6.75
- Quarter ended Dec 31, 2025: revenue $3.88B, net income $845M, EPS 7.78
- Quarter ended Sep 30, 2025: revenue $3.75B, net income $1.46B, EPS 13.62
Famous investors holding REGN
- Mason Hawkins (Southeastern Asset Management): $95.0M, 5.0% of the portfolio
- Two Sigma (Two Sigma Investments): $409M, 0.3% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $92.4M, 0.1% of the portfolio
- Ray Dalio (Bridgewater Associates): $32.0M, 0.1% of the portfolio
- Izzy Englander (Millennium Management): $147M, 0.1% of the portfolio
- Ken Griffin (Citadel Advisors): $370M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $28.9M, 0.0% of the portfolio
Largest institutional holders of REGN
- VANGUARD GROUP INC — $7.00B
- BlackRock, Inc. (BLK) — $5.68B
- VANGUARD CAPITAL MANAGEMENT LLC — $4.13B
- DODGE & COX — $3.04B
- STATE STREET CORP (STT, STT-PG) — $3.01B
- Invesco Ltd. (IVZ) — $2.46B
- JPMORGAN CHASE & CO (JPM, AMJB, VYLD, JPM-PC, JPM-PD, JPM-PJ, JPM-PK, JPM-PL, JPM-PM) — $2.38B
- VANGUARD PORTFOLIO MANAGEMENT LLC — $1.98B
- FRANKLIN RESOURCES INC (BEN) — $1.73B
- GEODE CAPITAL MANAGEMENT, LLC — $1.63B
Recent REGN insider trades
- Oct 14, 2026: Murphy Andrew J sold 4,147 shares ($3.20M)
- Sep 3, 2026: McCourt Marion sold 2,346 shares ($2.00M)
- Sep 2, 2026: Guarini Kathryn sold 400 shares ($340K)
- Aug 10, 2026: Zoghbi Huda Y sold 800 shares ($640K)
Members of Congress trading REGN
- May 15, 2026: Gilbert Ray Cisneros, Jr. sold $1.00K–$15.0K
- Feb 12, 2026: Julia Letlow bought $1.00K–$15.0K
- Nov 18, 2025: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- May 15, 2025: Robert P. Bresnahan, Jr. bought $1.00K–$15.0K
- Apr 10, 2025: Byron Donalds sold $1.00K–$15.0K
- Apr 10, 2025: Byron Donalds sold $1.00K–$15.0K
- Apr 8, 2025: Robert P. Bresnahan, Jr. sold $1.00K–$15.0K
- Apr 7, 2025: Jefferson Shreve sold $15.0K–$50.0K
- Apr 1, 2025: Julie Johnson sold $1.00K–$15.0K
- Feb 25, 2025: Robert P. Bresnahan, Jr. sold $1.00K–$15.0K
5%+ owners
- Vanguard Capital Management: 7.4% (Schedule 13G, filed Apr 30, 2026)
Who owns the most REGN stock?
The largest institutional holders of REGENERON PHARMACEUTICALS, INC. in the latest 13F filings are VANGUARD GROUP INC ($7.00B), BlackRock, Inc. (BLK) ($5.68B), VANGUARD CAPITAL MANAGEMENT LLC ($4.13B).
Are insiders buying or selling REGN?
Over the last 12 months insiders bought $0 and sold $16.1M of REGENERON PHARMACEUTICALS, INC. stock on the open market (SEC Form 4).
Which famous investors own REGN?
Mason Hawkins, Two Sigma, Renaissance Technologies, Ray Dalio, Izzy Englander.
What was REGN's revenue last quarter?
REGENERON PHARMACEUTICALS, INC. reported revenue of $4.29B for the quarter ended June 30, 2026, with net income of $1.30B.
Which ETFs hold REGN?
355 ETFs and mutual funds hold it among their top 100 positions, including DODGX, QQQ, PEIYX, VGHAX.